Dr. Robert Z. Orlowski, MD

Medicare patients and services

Medicare patients, 2024

223

Services billed

764

Patients’ average age

74

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 9 companies reported 20 payments worth $17,403 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 12 industry-funded studies in 2025, from 7 companies. The companies reported $2,328,635 in research payments for these studies, mostly to the institutions running them.

• A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05828511
• Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination with Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma
  Sanofi-aventis U.S. LLC
• A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED…
  Celgene Corporation
• Study name not reported
  Sanofi-aventis U.S. LLC
• Study name not reported
  Sanofi US Services Inc.
• A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED…
  E.r. Squibb & Sons, L.l.c.
• Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
  Menarini Silicon Biosystems, Inc. · Recruiting · NCT06105554
• A Phase 1/2 Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed …
  Celgene Corporation
• A Phase 1/2 Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed …
  E.r. Squibb & Sons, L.l.c.
• A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
  Celgene Corporation · Terminated · NCT03374085

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Houston

• Kanza S. Abbas, M.D.
• Joel W. Abramowitz, M.D., PHD
• Vahid Afsharkharghan, M.D.
• Sairah Ahmed, MD
• Talha Aijaz, MD
• Neal S. Akhave, MD
• Neha Akkad, MD
• Ajlan Al Zaki, MD, PHD